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Abstract Matrix metalloproteinase 9 (MMP-91gelatinase B) 
has recently been proposed to participate in the destruction of 
articular cartilage. Here, we report that interleukin 1 ([L-l) 
enhances the production of the precursor of MMP-9 in rabbit 
articular chondrocytes in primary culture, and this IL-l-mediated 
production of proMMP-9 is greatly augmented by cyclooxyge- 
nase inhibitors such as diclofenac and indomethacin, whereas the 
constitutive production of proMMP-2 (progelatinase A) is not 
modulated by IL-1 and/or cyclooxygenase inhibitors. Exogenous 
prostaglandin (PG) E1 and PGE2 suppress the proMMP-9 pro- 
duction in a dose-dependent manner. Similar results are also 
obtained with cultured rabbit synoviocytes. These results provide 
the first evidence that PGE down-regulates the production of 
proMMP-9 in chondrocytes and synoviocytes. Thus, cyclooxyge- 
nase inhibitors probably exert undesirable catabolic actions on 
the maintenance of articular cartilage under inflammatory condi- 
tions. 
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1. Introduction 
The destruction of connective tissue matrix components 
under pathological conditions uch as in rheumatoid arthritis 
(RA) and osteoarthritis (OA) causes the impairment of joint 
functions, and matrix metalloproteinases (MMPs) are consid- 
ered to play a critical role in these processes [1,2]. In particular, 
MMP-1 (interstitial collagenase, EC 3.4.24.7), which specifi- 
cally degrades native types I, II and III collagen [3], and MMP- 
3 (stromelysin 1, EC 3.4.24.17), which digests proteoglycans 
and collagen types IX and X [4-8], are probably key enzymes 
involved in the pathological destruction of cartilage. In addi- 
tion to these two enzymes it has been suggested that MMP-9 
(gelatinase B, EC 3.4.24.35) plays a role in the degradation of
cartilage since it is expressed in osteoarthritic cartilage [9] and 
is able to degrade proteoglycans [10]. 
In articular chondrocytes and synoviocytes, IL-1 is known 
to induce and/or augment the production of proMMPs-1 and 
-3 as well as prostaglandin (PG) E. These MMPs eventually 
participate in the destruction of connective tissue matrices 
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Abbreviations: MMP, matrix metalloproteinase; DMEM, Dulbecco's 
modified Eagle's medium; LAH, lactalbumin hydrolysate; FBS, fetal 
bovine serum; TPA, 12-O-tetradecanoylphorbol 13-acetate; rhlL-1, 
recombinant human interleukin 1; SDS-PAGE, sodium dodecyl sul- 
fate-polyacrylamide gel lectrophoresis; PG, prostaglandin. 
[11,12]. Recently, it was also reported that PGE suppresses the 
production of proMMP-1 in human fibroblasts [13,14] and 
rabbit synoviocytes [13]. Like proMMPs-1 and -3, the produc- 
tion of proMMP-9 is elevated in rabbit articular chondrocytes 
when treated with IL-1 [15,16]. However, little is known about 
the regulatory effect of PGE on the production of proMMP-9 
in chondrocytes. 
We have therefore xamined the effects of cyclooxygenase 
inhibitors and PGE on the production of proMMP-9 in rabbit 
articular chondrocytes, and report here that IL-1 enhances the 
production ofproMMP-9, and PGE1 and PGE2 down-regulate 
the production of proMMP-9. On the other hand, cyclooxyge- 
nase inhibitors uch as diclofenac and indomethacin further 
augmented the IL-l-mediated production of proMMP-9, indi- 
cating that these inhibitors may exert unfavorable effects for 
the maintenance of the cartilage under inflammatory condi- 
tions. 
2. Materials and methods 
2.1. Materials 
The following reagents were obtained commercially: Dulbecco's 
modified Eagle's medium (DMEM) from Gibco, Grand Island, NY, 
USA; bacterial collagenase (CLS1) from Worthington Biochemicals 
Corp., Freehold, NJ, USA; fetal-bovine s rum (FBS) from Whittaker 
Bioproducts Inc., Walkersville, MD, USA; diclofenac, indomethacin, 
lactalbumin hydrolysate (LAH), Nitro blue tetrazolium, 5-bromo-4- 
chloro-3-indolyl phosphate, alkaline phosphatase-conjugated donkey 
anti-(sheep IgG)IgG, 12-O-tetradecanoylphorbol 13-acetate (TPA) 
from Sigma Chemical Co., St. Louis, MO, USA; PGE1 and PGE2 from 
Funakoshi, Tokyo, Japan; trypsin from Difco Laboratories, Detroit, 
MI, USA. Recombinant human IL-lc~ (rhlL-1; 2 x 10 7 units/mg) was 
kindly supplied by Dainippon Pharmaceutical Co., Suita, Osaka, 
Japan. Sheep anti-(human proMMP-9)antiserum and purified 
proMMP-9 of HT1080 fibrosarcoma cells were kindly provided by Dr. 
H. Nagase of the University of Kansas Medical Center, Kansas City, 
KS, USA. Other reagents used were the same as in a previous paper 
[17]. 
2.2. Cell culture of rabbit chondrocytes and synoviocytes 
Rabbit articular chondrocytes were prepared by the method of Green 
[18] with slight modifications. Articular cartilage removed from the 
knee joints of male Japanese white rabbits weighing 0.3~0.5 kg was 
initially digested with 0.125% (w/v) trypsin/DMEM, 200 units/ml peni- 
cillin and 200/.tg/ml streptomycin at 37°C for 1 h and then treated with 
0.1% (w/v) bacterial collagenase, 10% (v/v) FBS/DMEM for 2 h. The 
dispersed chondrocytes were recovered by centrifugation at 700 x g and 
4°C for 5 rain and then washed once with PBS(-). Chondrocytes were 
suspended in 10% (v/v) FBS/DMEM/antibiotics, filtered through a 
150-mesh nylon screen and resuspended at a cell density of 5 x 105 
cells/ml. An aliquot (1 ml) of the cell suspension was placed in each well 
of 24 multiwell plates and cultured to confluence under 5% CO2/95% 
air at 37°C. Cells at the primary culture were used for all experiments. 
Rabbit synoviocytes were also prepared and subcultured in a culture 
of 10% (v/v) FBS/DMEM/antibiotics a described by Vater et al. [19]. 
For subsequent experiments, confluent cells were trypsinized, sus- 
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pended in 10% (v/v) FBS/DMEM/antibiotics and then plated in 24 
multiwell plates. Cells up to the 4th passage were used for the experi- 
ments. 
2.3. Treatment of rabbit cells and preparation of culture media 
To estimate the production proMMP-9 and proMMP-2, the culture 
medium was changed to DMEM/0.2% (w/v) LAH after confluence, and 
cyclooxygenase inhibitors and other reagents were added to the me- 
dium as an ethanol solution. The final ethanol concentration was 0. 1% 
(v/v) in all cultures, and the same amount of vehicle was added to the 
control cultures. The harvest culture media were stored at -20°C until 
use .  
2.4. Gelatin zymography 
Gelatinase activity in the culture media was analyzed by gelatin 
zymography as described previously [17]. An aliquot (12 pl) of har- 
vested culture media was subjected to SDS-PAGE [20] with an 8.5% 
(w/v) acrylamide slab gel containing 0.6 mg/ml gelatin under non- 
reducing conditions. Then the SDS in the gel was removed by rinsing 
with 50 mM Tris-HC1, 5 mM CaC12, 1/zM ZnC12, 0.02% (w/v) NAN3, 
2.5% (v/v) Triton X-100 (pH 7.5). The gel was then incubated in20 nil 
of the same buffer without Triton X-100 for 2 h at 37°C. After incuba- 
tion, the gel was stained with 0.1% (w/v) Coomassie brilliant blue in 
50% (v/v) methanol/20% (v/v) acetic acid, and destained with 1% (v/v) 
formic acid/30% (v/v) methanol. 
2.5. Western blotting for proMMP-9 
Each sample (1.5 ml) of harvested and mixed culture media from 
triplicate wells was mixed with a 1/5 vol. of 20% (w/v) trichloroacetic 
acid. The resultant precipitates were dissolved in reducing SDS-PAGE 
sample buffer [20], and then subjected to SDS-PAGE with an 8.5% 
(w/v) acrylamide slab gel under reducing conditions. Afterwards the 
electrophoresis proteins in the gel were electro-transferred onto a nitro- 
cellulose membrane. The membrane was reacted with sheep anti- 
(human proMMP-9)antiserum which was then complexed with alkaline 
phosphatase-conjugated donkey anti-(sheep IgG)IgG. Immunoreactive 
proMMP-9 was visualized indirectly with 5-bromo-4-chloro-3-indolyl 
phosphate and Nitro blue tetrazolium as described previously [21]. 
2.6. Detrmination of protein and radioimmunoassay for PGE2 
Cellular protein was dertermined by the method of Lowry et al. [22] 
using bovine serum albumin as a standard. PGE2 in culture media was 
measured by a commercial radioimmunoassay kit (Daiichikagaku-Ya- 
kuhin Co., Tokyo, Japan) according to the manufacturer's in tructions. 
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3. Results 
3.1. Gelatinolytic activities in rabbit articular chondrocytes 
When the culture media of rabbit articular chondrocytes 
were subjected to gelatin-zymography, gelatinolytic activity of 
68 kDa corresponding to proMMP-2 (gelatinase A, EC 
3.4.24.24) was constitutively expressed (Fig. 1A, lane 1). The 
expression of proMMP-2 was not modulated even when cells 
were treated with rhlL-1 and/or TPA (Fig. 1A, lanes 2-4). In 
addition to proMMP-2, chondrocytes produced a trace amount 
of 88 kDa-gelatinolytic a tivity (Fig. 1A, lane 1), and this activ- 
ity was augmented by treating cells with rhlL-1 (Fig. 1A, lane 
2). TPA synergistically enhanced the IL-1-mediated production 
of gelatinolytic activity (Fig. 1A, lane 4), although alone it was 
not effective, as reported previously [16]. Western blotting anal- 
ysis of the 88 kDa-gelatinolytic activity with an antibody of 
human proMMP-9 has identified it as rabbit proMMP-9 (Fig. 
1B). 
3.2. Effects of cyclooxygenase inhibitors, diclofenac and 
indomethacin on the production of  proMMP-9 in rabbit 
chondrocytes and synoviocytes 
When rabbit chondrocytes were treated with rhlL-1 or both 
TPA and rhlL-1 in the presence of a cyclooxygenase inhibitor, 
diclofenac, the production of proMMP-9 was greatly enhanced 
in a dose-dependent manner of the inhibitor (Fig. 2A). Diclofe- 
nac, however, did not modulate the production of proMMP-9 
in intact or the TPA-treated cells (Fig. 2A). Indomethacin, 
another cyclooxygenase inhibitor, similarly enhanced the pro- 
duction of proMMP-9 (Fig. 2B). On the other hand, these 
cyclooxygenase inhibitors did not modulate the production of 
proMMP-2, indicating that the stimulatory effects of these in- 
hibitors are mainly on proMMP-9 between the two gelatinases. 
High levels of MMPs including MMP-1/interstitial collage- 
nase and MMP-3/stromelysin 1 are found in synovial tissues 
with RA and OA [11,12], but little is known about the produc- 
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Fig. 1. Identification of92 kDa-gelatinolytic a tivity from rabbit articular chondrocytes. Confluent rabbit chondrocytes in 24-multiwell plates were 
treated with rhlL-1 (1 ng/ml) and/or TPA (10 nM) in 1.0 ml of 0.2% (w/v) LAH/DMEM for 48 h, and then samples of harvested and mixed culture 
media from triplicate wells were subjected to gelatin zymography (A) and Western blotting (B), as described in the text. Three independent experiments 
were reproducible, and typical data are shown. Lane 1, non-treated control cells; lane 2, rhlL-1; lane 3, TPA and lane 4, rhlL-1 plus TPA. HT indicates 
the purified proMMP-9 (1/zg) from HT1080 fibrosarcoma cells. 
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Fig. 2. Effects of cyclooxygenase inhibitors, diclofenac and indomethacin o  the production of proMMP-9 in rabbit articular chondrocytes. Confluent 
rabbit articular chondrocytes in 24-multiwell plates were treated with rhlL-1, TPA and/or a cyclooxygenase inhibitor in 1.0 ml of 0.2% (w/v) 
LAH/DMEM for 48 h, and then an aliquot (12/21) of the harvested and mixed culture media from triplicate wells was subjected to gelatin zymography, 
as described in the text. Three independent experiments were reproducible, and typical data are represented. (A) Diclofenac; (B) indomethacin. 
tion of MMP-9 in rabbit synoviocytes. Therefore, similar ex- 
periments were conducted with the cultured rabbit synovio- 
cytes. As in the case of chondrocytes, rhlL-1 enhanced the 
production of proMMP-9, but not proMMP-2 in synoviocytes 
(Fig. 3A and B, lane 5). Both diclofenac and indomethacin 
further augmented the IL- l - induced production of proMMP-9 
in synoviocytes (Fig. 3A and B, lanes 6-8), whereas the inhib- 
itors did not modulate the production of proMMP-2. These 
results indicate that the effect of cyclooxygenase inhibitors is 
not only on articular chondrocytes but also on synoviocytes. 
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3.3. Suppression of production of proMMP-9 by PGE1 and 
PGE2 in rabbit articular chondrocytes 
To investigate the mechanism of the action of cyclooxyge- 
nase inhibitors on the production of proMMP-9, we have ex- 
amined the effects of PGE1 and PGE2, since these inhibitors 
effectively diminish the production of PGEs in chondrocytes 
and fibroblasts [23], and rabbit articular chondrocytes are re- 
ported to produce predominantly PGE2 [24]. Indeed, when 
confluent rabbit chondrocytes were treated with 1 ng/ml of 
rhlL-1, the accumulation of extracellular PGE2 was about 30- 
proMMP-2  .-> 
rhlL-lc~ (ng/ml)  
Diclo. ( - log[M])  
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Fig. 3. Augmentation of IL-1-induced production proMMP-9 by diclofenac and indomethacin i  rabbit synoviocytes. Confluent rabbit synoviocytes 
at the fourth passage in 24-multiwell plates were treated with rhlL-1, diclofenac and/or indomethacin for 48 h in 1.0 ml of 0.2% (w/v) LAH/DMEM, 
and then an aliquot (12/21) of harvested and mixed culture media from triplicate wells was subjected to gelatin zymography as described in the text. 
Three independent experiments were reproducible, and typical data are shown. (A) diclofenac; lane 1, non-treated control cells; lanes 2-4, diclofenac 
(1 × 10 -9, 1 x 10 -8 and 1 x 10 -7 M, respectively), lane 5, rhlL-1 (1 ng/ml); lanes 6-8, rhlL-1 (1 ng/ml) plus diclofenac (the same as lanes 2-4). (B) 
indomethacin; lane 1, non-treated control cells, lanes 2-4, indomethacin (1 × 10 -7, 1 × 10 -6 and 1 × 10 -5 M, respectively), lane 5, rhlL-1 (1 ng/ml) and 
lanes 6-8, rhlL-1 (1 ng/ml) plus indomethacin (the same as lanes 2-4). 
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Fig. 4. Effects of PGE 1 and PGE2 on the constitutive and IL-1-mediated production of proMMP-9 in rabbit articular chondrocytes. Confluent rabbit 
chondrocytes were treated with rhIL-1 (1 ng/ml) and/or various concentrations of PGE for 48 h, and other experimental conditions were the same 
as in Fig. 2. Lane 1, non-treated control cells; lanes 2-4, PGE (1 x 10 -8, 1 × 10 -7 and 1 × 10 -6 M, respectively); lane 5, rhIL-1 (1 ng/ml) and lanes 
6-8, rhIL-1 (1 ng/ml) plus PGE (1 x 11~8, 1 × 10,7 and 1 x 10-6 M, respectively). (A) PGE2; (B) PGE1. 
times higher than that by non-treated control cells, and in- 
domethacin reduced the IL-1-mediated accumulation f PGE2 
to the level of the non-treated control cells (Table 1). When the 
chondrocytes were treated with PGE1 or PGE2 both the consti- 
tutive and the IL-l-enhanced production of proMMP-9 was 
suppressed in a dose-dependent manner (Fig. 4A and B, lanes 
2~, and 6-8). The production of proMMP-2 was not affected 
by PGE1 or PGE2. These results uggest that both PGE1 and 
PGE2 down-regulate he production of proMMP-9. Thus the 
enhancement of proMMP-9 production caused by cyclooxyge- 
nase inhibitors in chondrocytes and synoviocytes is due to the 
decreased level of cellular PGEs. 
4. Discussion 
The roles of PGEs at inflammatory sites are undefined: e.g. 
PGE is considered to be a mediator of acute-phase inflamma- 
tion since it increases vascular permeability [25]. In contrast, 
PGEs also exert anti-inflammatory effects in chronic inflamma- 
tions [25] and also suppress adjuvant arthritis in rat [26]. Fur- 
thermore, PGE2 effectively inhibits the synthesis of inflamma- 
tory cytokine of IL-1 in macrophages [27]. In view of these 
observations, PGEs are very likely to suppress chronic inflam- 
mation. This hypothesis might be further supported by the 
observations concerning indomethacin: i.e. indomethacin sup- 
presses the biosynthesis of proteoglycans in articular cartilage 
[28-30] and rat chondrocytes [24,31], and accelerates the prolif- 
eration of human synoviocytes [32]. It is also reported that 
cyclooxygenase inhibitors never interfere with the progress of 
arthritis [33]. 
Concerning the production of proMMPs, especially 
proMMP-9, we have observed that both PGE1 and PGE2 sup- 
press proMMP-9 production in cultured rabbit chondrocytes, 
and the IL-l-mediated production was effectively augmented 
by cyclooxygenase inhibitors. A similar enhanced production 
of proMMP-9 by the inhibitors was also detected in human 
rheumatoid synoviocytes (A. Mukaiyama, A. Ito and Y. Mori, 
unpublished work). The mechanism of action of both PGE 1 
and PGE2 on the production of proMMPs, especially 
proMMP-9, is unclear. From this point of view, we observed 
that cAMP and intracellular cAMP-modulating reagents, uch 
as forskolin (adenylate cyclase activator) and 3-isobutyl-1- 
methylxanthine (phosphodiesterase inhibitor) effectively mim- 
icked the suppressive ffect of PGEs on the production of 
proMMPs including proMMP-9 in rabbit chondrocytes (T. 
Nose, A. Ito, T. Kubo and Y. Mori, unpublished work). In 
addition, PGE1 enhanced the accumulation of intracellular 
cAMP: i.e. the level of PGEl-treated cells was about 6-times 
higher than that of untreated control cells (17.4+0.1 vs. 
103.2+14.8 fmolStg cellular proteirgl0 min). It is noteworthy, 
however, that PGE2 did not modulate the intracellular cAMP 
level in chondrocytes (data not shown), but the cells produced 
mainly PGE2. These observations therefore suggest hat the 
suppressive effect of PGE1, but not PGE2, on the production 
of proMMPs may be a result of the increase in intracellular 
cAME whereas the action mechanism ofPGE2 on proMMP-9 
production is obscure and remains to be clarified in future 
studies. 
In conclusion, we have demonstrated for the first time that 
in rabbit chondrocytes the production of proMMP-9 is down- 
Table 1 
Effect of indomethacin o  the IL-l-mediated production of PGE2 in 
rabbit articular chondrocytes 
Treatment PGE2 production 
pg/ctg cellular protein/24 h) 
Control 0.52 + 0.06 
rhlL-1 17.15 + 2.02 (P < 0.001 a) 
rhlL-1 plus indomethacin 0.52 + 0.02 (P < 0.001 b) 
Confluent rabbit articular chondrocytes in 100 mm-diameter dishes 
were treated with 15 ml of 0.2% (w/v) LAH/DMEM containing rhIL-1 
(1 ng/ml) and/or indomethacin (10/IM) for 24 h. PGE2 in harvested 
culture media was determined bya radioimmunoassay kit, as described 
in the text. Data are means + S.D. for three wells. Two independent 
experiments were reproducible, and typical data are represented. " and 
b significantly different from control and rhlL-l-treated cells, respec- 
tively. 
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regulated by PGE1 and PGE2, and that the cyclooxygenase 
inhibitors indomethacin and diclofenac further augment he 
IL-l-mediated production of proMMP-9. Therefore, our pres- 
ent findings and previous reports [24,28-33] strongly suggest 
that the cyclooxygenase inhibitors are very likely to exert unde- 
sirable actions on the maintenance of articular cartilage, and 
that both PGE1 and PGE2 play an anti-inflammatory role in 
the destruction of articular cartilage. 
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